1887
3 - The International and Scientific Conference of Alnahrain College of Medicine and Colleges of Medicine in Iraq confronting COVID-19 Pandemic (ISMC-2022)
  • ISSN: 1999-7086
  • EISSN: 1999-7094

Abstract

Since December 2019, coronavirus disease 2019 (COVID-19), which is caused by SARS-CoV-2, has spread locally in Wuhan, China, and later on, a worldwide outbreak occurred. Invasive fungal infections can cause complications in critically ill immunocompromised patients of COVID-19, especially those admitted to intensive care units and who required mechanical ventilation. have been the most common pathogenic species, followed by other spp. Mannan is a major component of the cell wall and can be detected by the enzyme-linked immunosorbent assay (ELISA) in blood and other fluids. Invasive pulmonary aspergillosis is considered a life-threatening infection, especially among immunocompromised patients. COVID-19-associated pulmonary aspergillosis has emerged as an important complication among patients in the intensive care units. Galactomannan (GM) is a major cell-wall component of spp. and can be found in body fluids. Blood GM can be detected by the enzyme immunoassay. The aim of the current study is to assess the frequency of aspergillosis and candidiasis among COVID-19 patients in some hospitals in Baghdad by using GM and mannan biomarkers. During the period from February 2020 to May 2021, 175 COVID-19 blood samples of patients were collected and a sandwich ELISA test was performed to detect GM Ag of spp. and mannan Ag of spp. Regarding C-reactive protein (CRP), significant differences were seen among /COVID-19 patients ( = 0.029). Regarding sex and age group, the results indicated that of a total of 175 adult patients with positive COVID-19, more than half of the patients were males. Regarding the distribution of mannan Ag and GM Ag in COVID-19 patients, it was seen that out of the 175 patients, 167 (95.43%) mannan Ag were negative and only 8 (4.57%) were positive, and 170 (79.14%) GM Ag were negative and only 5 (2.86%) were positive. It was also seen that 2 patients (1.14%) who had both mannan and GM were positive and 173 (98.6%) were negative. No statistically significant difference was seen in candidiasis and aspergillosis among patients with COVID-19 regarding age group, sex, underlying chronic diseases (hypertension and diabetes mellitus), and biochemical tests. COVID-19 infections increased with age and were seen more in males than in females. The percentage of infection with and spp. among COVID-19 patients was not significant, and this may come from the random collection of samples from patients with different stages of illness. A significant correlation was found between GM Ag in COVID-19 patients and the CRP test.

Loading

Article metrics loading...

/content/journals/10.5339/jemtac.2022.ismc.7
2022-06-15
2022-07-02
Loading full text...

Full text loading...

/deliver/fulltext/jemtac/2022/3/jemtac.2022.ismc.7.html?itemId=/content/journals/10.5339/jemtac.2022.ismc.7&mimeType=html&fmt=ahah

References

  1. Yang X, Yu Y, Xu J, et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. Lancet Respir Med. 2020; 8:(5):475–81.
    [Google Scholar]
  2. Walsh TJ, Dixon DM. In: Baron S. Editor. Baron's Medical Microbiology. Galveston, TX: University of Texas Medical Branch at Galveston; 1996.
    [Google Scholar]
  3. Eckert L.O., Lentz G.M. Infections of the lower and upper genital tracts. Vulva, vagina, cervix, toxic shock syndrome, endometritis and salpingitis. In: Lentz G.M., Lobo R.A., Gershenson D.M., Katz V.L., eds. Comprehensive gynecology. 6th ed. Philadelphia: Mosby Elsevier; 2013: 519–59.
    [Google Scholar]
  4. Kourkoumpetis T, Manolakaki D, Velmahos G, et al. Candida infection, and colonization among non-trauma emergency surgery patients. Virulence 2010; 1:(5):359–66.
    [Google Scholar]
  5. Van der Meer JW, van de Veerdonk FL, Joosten LA, Kullberg BJ, Netea MG. Severe Candida spp. infections: new insights into natural immunity. Int J Antimicrob Agents 2010; 36:(2):58–62.
    [Google Scholar]
  6. Mikulska M, Calandra T, Sanguinetti M, Poulain D, Viscoli C. The use of mannan antigen and anti-mannan antibodies in the diagnosis of invasive candidiasis: recommendations from the Third European Conference on Infections in Leukemia. Crit Care 2010; 14:(6).
    [Google Scholar]
  7. Oppe MM. Kenntnis der Schimmelmykosen beim Menschen. Zbl Allg Path. 1897;:(8):301–6.
    [Google Scholar]
  8. Gangneux JP, Bougnoux ME, Dannaoui E, Cornet M, Zahar JR. Invasive fungal diseases during COVID-19: we should be prepared. J Mycol Med. 2020; 30:(2):100971. doi: 10.1016/j.mycmed.2020.100971.
    [Google Scholar]
  9. Reiss E, Lehmann P. Galactomannan antigenemia in invasive aspergillosis. Infect Immun. 1979; 25:(1):357–65.
    [Google Scholar]
  10. Verweij PE, Poulain D, Obayashi T, Patterson TF, Denning DW, Ponton J. Current trends in the detection of antigenemia, metabolites, and cell wall markers for the diagnosis and therapeutic monitoring of fungal infections. Med Mycol. 1998; 36:(Suppl. 1):146–55. PMID: 9988503.
    [Google Scholar]
  11. Rawlings SA, Heldt S, Prattes J, et al. Using interleukin 6 and 8 in blood and bronchoalveolar lavage fluid to predict survival in hematological malignancy patients with suspected pulmonary mold infection. Front Immunol. 2019;:10:1798. doi:10.3389/fimmu.2019.01798.
    [Google Scholar]
  12. Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet 2020;:95:507–13.
    [Google Scholar]
  13. Xiong S, Liu L, Lin F, et al. Clinical characteristics of 116 hospitalized patients with COVID-19 in Wuhan, China: a single-centered, retrospective, observational study. BMC Infect Dis. 2020; 20:(1):787. doi:10.1186/s12879-020-05452-2. PMID: 33092539; PMCID: PMC7578439.
    [Google Scholar]
  14. Ko JY, Danielson ML, Town M, et al.; COVID-NET Surveillance Team. Risk factors for coronavirus disease 2019 (COVID-19)-associated hospitalization: COVID-19-Associated Hospitalization Surveillance Network and Behavioral Risk Factor Surveillance System. Clin Infect Dis. 2021; 72:(11):e695–703. doi:10.1093/cid/ciaa1419. PMID: 32945846; PMCID: PMC7543371.
    [Google Scholar]
  15. Bwire GM. Coronavirus: why men are more vulnerable to Covid-19 than women? SN Compr Clin Med. 2020; 2:(7):874–6. doi:10.1007/s42399-020-00341.
    [Google Scholar]
  16. Grasselli G, Zangrillo A, Zanella A, et al. COVID-19 Lombardy ICU Network. Baseline characteristics and outcomes of 1591 patients infected with SARS-CoV-2 admitted to ICUs of the Lombardy Region, Italy. JAMA 2020; 323:(16):1574–81. doi:10.1001/jama.2020.5394.
    [Google Scholar]
  17. Kim L, Garg S, O'Halloran A, et al. Risk factors for intensive care unit admission and in-hospital mortality among hospitalized adults identified through the US Coronavirus Disease 2019 (COVID-19)-Associated Hospitalization Surveillance Network (COVID-NET). Clin Infect Dis. 2021; 72:(9):e206–14. doi:10.1093/cid/ciaa1012.
    [Google Scholar]
  18. Richardson S, Hirsch JS, Narasimhan M, et al. Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City area [published correction appears in JAMA 2020;323(20):2098]. JAMA 2020; 323:(20):2052–9. doi:10.1001/jama.2020.6775.
    [Google Scholar]
  19. Lei Y, Song Y, Shu Y, et al. Fungal antigenemia in patients with severe coronavirus disease 2019 (COVID-19): the facts and challenges. J Microbiol Immunol Infect. 2020; 53:(4):657–9. doi:10.1016/j.jmii.2020.05.010.
    [Google Scholar]
  20. Kayaaslan B, Eser F, Kaya Kalem A, et al. Characteristics of candidemia in COVID-19 patients: increased incidence, earlier occurrence, and higher mortality rates compared to non-COVID-19 patients. Mycoses 2021; 64:(9):1083–91. doi:10.1111/myc.13332. Epub 2021 Jun 16. PMID: 34085319; PMCID: PMC8242769.
    [Google Scholar]
  21. Xu J, Yang X, Lv Z, et al. Risk factors for invasive aspergillosis in patients admitted to the intensive care unit with coronavirus disease 2019: a multicenter retrospective study. Front Med. 2021;:8:753659. doi:10.3389/fmed.2021.753659. PMID: 34869450; PMCID: PMC8635191.
    [Google Scholar]
  22. Bretagne S, Sitbon K, Botterel F, Dellière S, Letscher-Bru V, et al. COVID-19-associated pulmonary aspergillosis, fungemia, and pneumocystosis in the intensive care unit: a retrospective multicenter observational cohort during the first French pandemic wave. Microbiol Spectrum 2021; 9:(2):e0113821. doi:10.1128/Spectrum.01138-21.
    [Google Scholar]
  23. Lahmer T, Kriescher S, Herner A, et al. Invasive pulmonary aspergillosis in critically ill patients with severe COVID-19 pneumonia: results from the prospective AspCOVID-19 study. PLoS One 2021; 16:(3):e0238825. Published 2021 Mar 17. doi:10.1371/journal.pone.0238825.
    [Google Scholar]
  24. Das S, Gupta C, Jain C, et al. Utility of serum galactomannan in diagnosing COVID-19 patients with suspected IPA: an observational study in resource-limited settings. Eur Rev Med Pharmacol Sci. 2022;:26:710–4.
    [Google Scholar]
  25. Machado M, Valerio M, Álvarez-Uría A, et al. Invasive pulmonary aspergillosis in the COVID-19 era: an expected new entity. Mycoses 2021;:64:132–43.
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journals/10.5339/jemtac.2022.ismc.7
Loading
/content/journals/10.5339/jemtac.2022.ismc.7
Loading

Data & Media loading...

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error